Tivozanib is an anticancer chemotherapeutic and anti-angiogenic compound that inhibits VEGFR1/2/3, c-Kit, and PDGFR. Tivozanib is currently in clinical trials as a potential treatment for renal cell carcinoma. The antiangiogenic activity of tivozanib is exhibited by its ability to suppress development of choroidal neovascular (CNV) lesions and also to regress established CNV in animal models.
| Cas No. | 475108-18-0 |
|---|---|
| Purity | ≥98% |
| Formula | C22H19ClN4O5 |
| Formula Wt. | 454.86 |
| IUPAC Name | 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea |
| Synonym | AV-951 |
| Appearance | Grey powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | T3585 Info Sheet PDF |
|---|
Cowey CL. Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma. Drug Des Devel Ther. 2013 Jun 21;7:519-27. PMID: 23818763.
Hepgur M, Sadeghi S, Dorff TB, et al. Tivozanib in the treatment of renal cell carcinoma. Biologics. 2013;7:139-48. PMID: 23788831.
Kang S, Roh YJ, Kim IB. Antiangiogenic effects of tivozanib, an oral VEGF receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization in mice. Exp Eye Res. 2013 Jul;112:125-33. PMID: 23701975.
